Prognostication in Different Heart Failure Phenotypes: The Role of Circulating Biomarkers

Journal of Circulating Biomarkers

Volumn 5, Issue , 2016, Pages

  Berezin, Alexander E ^a  

^a ZAPORIZHZHIA STATE MEDICAL UNIVERSITY   (Ukraine)

Author keywords

Biomarkers; Heart Failure Phenotypes; Prognostication; Risk Stratification

Indexed keywords

EID: 84973400240     PISSN: None     EISSN: 18494544     Source Type: Journal    
DOI: 10.5772/62797     Document Type: Review

References (68)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ. Heart disease and stroke statistics — 2014 update: A report from the American Heart Association. Circulation. 2014; 129(3): e28–e292
2. Dunlay SM, Roger VL. Understanding the epidemic of heart failure: Past, present, and future. Curr Heart Fail Rep. 2014; 11(4): 404–15
3. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: An individual patient data meta-analysis. Eur Heart J. 2012; 33(14): 1750–7
4. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: Pathophysiology, diagnosis, and treatment. Eur Heart J. 2011; 32(6): 670–9
5. Wang J, Li Z, Chen J, Zhao H, Luo L, Chen C. Metabolomic identification of diagnostic plasma biomarkers in humans with chronic heart failure. Mol Biosyst. 2013; 9(11): 2618–26
6. Lekavich CL, Barksdale DJ, Neelon V, Wu JR. Heart failure preserved ejection fraction (HFpEF): An integrated and strategic review. Heart Fail Rev. 2015; 20(6): 643–53
7. Mavrea AM, Dragomir T, Bordejevic DA, Tomescu MC, Ancusa O, Marincu I. Causes and predictors of hospital readmissions in patients older than 65 years hospitalized for heart failure with preserved left ventricular ejection fraction in western Romania. Clin Interv Aging. 2015; 10: 979–90
8. Ueda T, Kawakami R, Nishida T, Onoue K, Soeda T, Okayama S. Left ventricular ejection fraction (EF) of 55% as cutoff for late transition from heart failure (HF) with preserved EF to HF with mildly reduced EF. Circ J. 2015; 79(10): 2209–15
9. Goto T, Wakami K, Fukuta H, Fujita H, Tani T, Ohte N. Patients with left ventricular ejection fraction greater than 58 % have fewer incidences of future acute decompensated heart failure admission and all-cause mortality. Heart Vessels. 2015 [Epub ahead of print]
10. Desta L, Jernberg T, Spaak J, Hofman-Bang C, Persson H. Heart failure with normal ejection fraction is uncommon in acute myocardial infarction settings but associated with poor outcomes: A study of 91 360 patients admitted with index myocardial infarction between 1998 and 2010. Eur J Heart Fail. 2015. doi: 10.1002/ejhf.416. [Epub ahead of print]
11. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr. Drazner MH. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62(16): e147–e239
12. Zile MR, Baicu CF. Biomarkers of diastolic dysfunction and myocardial fibrosis: Application to heart failure with a preserved ejection fraction. J Cardiovasc Transl Res. 2013; 6(4): 501–15
13. D'Elia E, Vaduganathan M, Gori M, Gavazzi A, Butler J, Senni M. Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: Critical appraisal and practical use. Eur J Heart Fail. 2015. doi: 10.1002/ejhf.430. [Epub ahead of print]
14. Kenchaiah S, Vasan RS. Heart Failure in Women — Insights from the Framingham Heart Study. Cardiovasc Drugs Ther. 2015; 29(4): 377–90
15. Kristensen SL, Køber L, Jhund PS, Solomon SD, Kjekshus J, McKelvie RS. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation. 2015; 131(1): 43–53
16. Rosenkranz S, Gibbs JS, Wachter R, De Marco T, Vonk-Noordegraaf A, Vachiéry JL. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2015. pii: Ehv512. [Epub ahead of print]
17. Wilcox JE, Fonarow GC, Ardehali H, Bonow RO, Butler J, Sauer AJ. “Targeting the heart” in heart failure: Myocardial recovery in heart failure with reduced ejection fraction. JACC Heart Fail. 2015; 3(9): 661–9
18. Katz AM, Rolett EL. Heart failure: When form fails to follow function. Eur Heart J. 2015 pii: Ehv548. [Epub ahead of print]
19. Beltrami M, Palazzuoli A, Ruocco G, Aspromonte N. The predictive value of plasma biomarkers in discharged heart failure patients: The role of plasma BNP. Minerva Cardioangiol. 2015 [Epub ahead of print]
20. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003; 362: 316–22
21. Gaggin HK, Januzzi JL, Jr. Natriuretic peptides in heart failure and acute coronary syndrome. Clin Lab Med. 2014; 34(1): 43–58
22. Wijk S Sanders-Van, van Empel V, Davarzani N, Maeder MT, Handschin R, Pfisterer ME. TIME-CHF investigators. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail. 2015; 17(10): 1006–14
23. Veien KT1, Jensen JK, Hildebrandt P, Gøtze JP, Nielsen OW, Køber L. Natriuretic peptides as cardiac markers in clinical practice. Ugeskr Laeger. 2010; 172(30): 2111–6
24. Omland T, Røsjø H, Giannitsis E, Agewall S. Troponins in heart failure. Clin Chim Acta. 2015; 443:78–84
25. Sherwi N, Pellicori P, Joseph AC, Buga L. Old and newer biomarkers in heart failure: From pathophysiology to clinical significance. J Cardiovasc Med (Hagerstown). 2013; 14(10): 690–7
26. Miller WL, Hartman KA, Burritt MF, Grill DE, Jaffe AS. Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 2009; 54(18): 1715–21
27. Vorovich E, French B, Ky B, Goldberg L, Fang JC, Sweitzer NK. Biomarker predictors of cardiac hospitalization in chronic heart failure: A recurrent event analysis. J Card Fail. 2014; 20(8): 569–76
28. Li Y, Zhang L, Jean-Charles PY, Nan C, Chen G, Tian J. Dose-dependent diastolic dysfunction and early death in a mouse model with cardiac troponin mutations. J Mol Cell Cardiol. 2013; 62: 227–36
29. Seliger SL, de Lemos J, Neeland IJ, Christenson R, Gottdiener J, Drazner MH. Older adults, “malignant” left ventricular hypertrophy, and associated cardiac-specific biomarker phenotypes to identify the differential risk of new-onset reduced versus preserved ejection fraction heart failure: CHS (cardiovascular health study). JACC Heart Fail. 2015; 3(6): 445–55
30. Neeland IJ, Drazner MH, Berry JD, Ayers CR, deFilippi C, Seliger SL. Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population. J Am Coll Cardiol. 2013; 61(2):187–95. doi: 10.1016/j.jacc.2012.10.012. Epub 2012
31. deFilippi CR, de Lemos JA, Tkaczuk AT, Christenson RH, Carnethon MR, Siscovick DS. Physical activity, change in biomarkers of myocardial stress and injury, and subsequent heart failure risk in older adults. J Am Coll Cardiol. 2012; 60(24): 2539–47
32. Zordoky BN, Sung MM, Ezekowitz J, Mandal R, Han B, Bjorndahl TC. Alberta HEART. Metabolomic fingerprint of heart failure with preserved ejection fraction. PLoS One. 2015; 10(5): e0124844
33. Sherwi N, Pellicori P, Joseph AC, Buga L. Old and newer biomarkers in heart failure: From pathophysiology to clinical significance. J Cardiovasc Med (Hagerstown). 2013; 14(10): 690–7
34. Lala RI, Puschita M, Darabantiu D, Pilat L. Galectin-3 in heart failure pathology — “another brick in the wall”? Acta Cardiol. 2015; 70(3): 323–31
35. Leone M, Iacoviello M. The predictive value of plasma biomarkers in discharged heart failure patients: Role of galectin-3. Minerva Cardioangiol. 2015 [Epub ahead of print]
36. Shah KS, Maisel AS. Novel biomarkers in heart failure with preserved ejection fraction. Heart Fail Clin. 2014; 10(3): 471–9
37. Miller WL, Saenger AK, Grill DE, Slusser JP, Bayes-Genis A, Jaffe AS. Prognostic value of serial measurements of soluble suppression of tumorigenicity 2 and galectin-3 in ambulatory patients with chronic heart failure. J Card Fail. 2015 doi: 10.1016/j.cardfail. 2015.07.017. [Epub ahead of print]
38. Lepojärvi ES, Piira OP, Pääkkö E, Lammentausta E, Risteli J, Miettinen JA. Serum PINP, PIIINP, galectin-3, and ST2 as surrogates of myocardial fibrosis and echocardiographic left venticular diastolic filling properties. Front Physiol. 2015; 6: 200
39. Gurel OM, Yilmaz H, Celik TH, Cakmak M, Namuslu M, Bilgiç AM. Galectin-3 as a new biomarker of diastolic dysfunction in hemodialysis patients. Herz. 2015; 40(5): 788–94
40. Yu X, Sun Y, Zhao Y, Zhang W, Yang Z, Gao Y. Prognostic value of plasma galectin-3 levels in patients with coronary heart disease and chronic heart failure. Int Heart J. 2015; 56(3): 314–8
41. Gruson D, Ferracin B, Ahn SA, Rousseau MF. Comparison of fibroblast growth factor 23, soluble ST2 and Galectin-3 for prognostication of cardiovascular death in heart failure patients. Int J Cardiol. 2015; 189: 185–7
42. de Boer RA, Daniels LB, Maisel AS, Januzzi JL, Jr. State of the Art: Newer biomarkers in heart failure. Eur J Heart Fail. 2015; 17(6): 559–69
43. Lupu S, Agoston-Coldea L. Soluble ST2 in ventricular dysfunction. Adv Clin Chem. 2015; 69: 139–59
44. Zhang R, Zhang Y, An T, Guo X, Yin S, Wang Y. Prognostic value of sST2 and galectin-3 for death relative to renal function in patients hospitalized for heart failure. Biomark Med. 2015; 9(5): 433–41
45. Quick S, Waessnig NK, Kandler N, Poitz DM, Schoen S, Ibrahim K. Soluble ST2 and myocardial fibrosis in 3T cardiac magnetic resonance. Scand Cardiovasc J. 2015; 49(6): 361–6
46. Kim MS, Jeong TD, Han SB, Min WK, Kim JJ. Role of soluble ST2 as a prognostic marker in patients with acute heart failure and renal insufficiency. J Korean Med Sci. 2015; 30(5): 569–75
47. Yao HC, Li XY, Han QF, Wang LH, Liu T, Zhou YH. Elevated serum soluble ST2 levels may predict the fatal outcomes in patients with chronic heart failure. Int J Cardiol. 2015; 186: 303–4
48. Zhou H, Ni J, Yuan Y, Deng W, Bian ZY, Tang QZ. Soluble ST2 may possess special superiority as a risk predictor in heart failure patients. Int J Cardiol. 2015; 186: 146–7
49. Ravassa S, Beloqui O, Varo N, Barba J, Lopez B, Beaumont J, Zalba G, Diez J, Gonzalez A. Association of cardiotrophin-1 with left ventricular systolic properties in asymptomatic hypertensive patients. J Hypertension. 2013; 31: 587–594
50. Caliskan S, Besli F, Yildirim A, Gungoren F, Alisir MF, Polat U. The relationship between Cardiotrophin-1 and Troponin-I in coronary arterial bypass grafting on the beating heart: A prospective study. Heart Surg Forum. 2015; 18(4): E146–50
51. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T. Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001; 38(5): 1485–90
52. Jougasaki M, Tachibana I, Luchner A, Leskinen H, Redfield MM, Burnett JC, Jr. Augmented cardiac cardiotrophin-1 in experimental congestive heart failure. Circulation. 2000; 101(1): 14–7
53. López B, Castellano JM, González A, Barba J, Díez J. Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension. Hypertension. 2007; 50(5): 977–83
54. López B, González A, Querejeta R, Barba J, Díez J. Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: Potential diagnostic implications. J Hypertens. 2009; 27(2): 418–24
55. Celik A, Sahin S, Koc F, Karayakali M, Sahin M, Benli I. Cardiotrophin-1 plasma levels are increased in patients with diastolic heart failure. Med Sci Monit. 2012; 18(1): CR25–31
56. Kapur NK, Wilson S, Yunis AA, Qiao X, Mackey E, Paruchuri V. Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure. Circulation. 2012; 125(22): 2728–38
57. Heffernan KS1, Kuvin JT, Patel AR, Karas RH, Kapur NK. Endothelial function and soluble endoglin in smokers with heart failure. Clin Cardiol. 2011; 34(12):729–33
58. Chen K, Mehta JL, Li D, Joseph L, Joseph J. Transforming growth factor beta receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II. Circ Res. 2004; 95: 1167–1173
59. Ikemoto T, Hojo Y, Kondo H, Takahashi N, Hirose M, Nishimura Y. Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases. Heart Vessels. 2012; 27(4): 344–51
60. Bills VL, Varet J, Millar A, Harper SJ, Soothill PW, Bates DO. Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia. Clin Sci (Lond). 2009; 116(3): 265–72
61. Kapur NK, Heffernan KS, Yunis AA, Parpos P, Kiernan MS, Sahasrabudhe NA. Usefulness of soluble endoglin as a noninvasive measure of left ventricular filling pressure in heart failure. Am J Cardiology. 2010; 106(12): 1770–1776
62. Berezin AE. Diabetes mellitus related biomarker: The predictive role of growth- differentiation factor-15. Diabetes Metab Syndr. 2015. doi: 10.1016/j.dsx.2015.09.016. [Epub ahead of print]
63. Adela R, Banerjee SK. GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: A translational prospective. J Diabetes Res. 2015; 2015: 490842
64. Eindhoven JA, van den Bosch AE, Oemrawsingh RM, Baggen VJ, Kardys I, Cuypers JA. Release of growth-differentiation factor 15 and associations with cardiac function in adult patients with congenital heart disease. Int J Cardiol. 2015; 202: 246–251
65. Cotter G, Voors AA, Prescott MF, Felker GM, Filippatos G, Greenberg BH. Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: Results from the RELAX-AHF study. Eur J Heart Fail. 2015. doi: 10.1002/ejhf.331. [Epub ahead of print]
66. Zhu ZD, Sun T. Association between growth differentiation factor-15 and chronic heart failure in coronary atherosclerosis patients. Genet Mol Res. 2015; 14(1): 2225–33
67. Sinning C, Zengin E, Zeller T, Schnabel RB, Blankenberg S, Westermann D. Candidate biomarkers in heart failure with reduced and preserved ejection fraction. Biomarkers. 2015; 20(4): 258–65
68. Chan MM, Santhanakrishnan R, Chong JP, Chen Z, Tai BC, Liew OW. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail. 2015. doi: 10.1002/ejhf.431. [Epub ahead of print]